There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.
Category:
Apparatus
-
-
Apparatus
Georgia Institute of Technology 3D printing heart valve model to improve the success rate of valve replacement
It is reported that researchers from Georgia Institute of Technology and Piemonte Heart Institute are using customized 3D printed heart valve models based on patients' heart CT scanning to improve the success rate of transcatheter aortic valve replacement (TAVR) surgery. Their aim is to avoid perivalvular leakage. This research has been published in JACC: Cardiovascular Imaging.
-
Apparatus
Major Breakthrough In 27 Years! This Cancer Vaccine Has Kept Deadly Brain Cancer Patients Alive For Over 8 Years!
A dendritic cell vaccine has shown excellent results in the treatment of glioblastoma, significantly extending the survival of patients with a good safety profile, according to new data from a global clinical trial. To date, patients who have benefited for the longest time have survived for more than eight years.
-
According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!
-
The Fraunhofer Institute in Germany has now developed two techniques that could make testing faster and cheaper.
-
Apparatus
New Drug For IDH1 Mutation/Relapsed/Refractory Acute Myeloid Leukaemia With Good Complete Remission Rates And Manageable Toxicity
The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.
-
The dental profession can use these tools as a guide to improve the sustainability of their working environment and to recognise their efforts by tracking progress.
-
SKB264 is currently in Phase II and Phase III clinical trials as a single agent/combination for multiple tumour types.
-
Apparatus
Specialising in RNA 3D structure prediction, Atomic AI wants to launch an RNA version of AlphaFold to accelerate drug discovery!
The impact of AlphaFold on protein structure prediction has been transformative.
-
Apparatus
New CAR-T Therapy CB-010, Granted Two FDA Designations And Three Patients Are Cancer-Free For Six Months!
According to an announcement from Caribou Biosciences, the FDA has granted advanced therapy designation in regenerative medicine for the cutting-edge CAR-T therapy CB-010 for the treatment of relapsed or refractory large B-cell lymphoma and fast track designation for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
